



## **GUJARAT TERCE LABORATORIES LIMITED**

**Date: 4<sup>th</sup> February, 2025**

To,  
Corporate Relations Department,  
Bombay Stock Exchange Limited,  
2<sup>nd</sup> Floor, P.J Towers,  
Dalal Street,  
Mumbai-400 001

**Scrip Code: 524314**

Dear Sir,

### **Subject: Outcome of Board Meeting**

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Schedule III to the said Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today i.e., Tuesday, 4<sup>th</sup> February, 2025 which commenced at 4:00 p.m. and concluded at 4:30 p.m. inter alia, have approved / noted the following:-

1. Approval of Unaudited Standalone Financial Results for the Quarter ended on December 31, 2024:

Upon recommendation of the Audit Committee, the Board of Directors have approved the Unaudited Standalone Financial Results as per Indian Accounting Standards (IND-AS) for the Quarter ended on December, 31, 2024 (enclosed herewith) and the same is also available on the website of the company at [www.gujaratterce.com/Investor](http://www.gujaratterce.com/Investor)





## **GUJARAT TERCE LABORATORIES LIMITED**

2. The Limited Review Report of the Statutory Auditors (M.A. Shah & Co.) is with unmodified opinion with respect to the Unaudited Standalone Financial Results of the Company for the Quarter year ended December 31, 2024 (enclosed herewith), the Board of Directors took note of the same.

We request you to please take the above information on your records.

Thanking you.

Yours faithfully,

**Gujarat Terce Laboratories Limited**

**Aalap Prajapati**  
**Managing Director & CEO**  
**(DIN: 08088327)**



**Encl.:**

1. Standalone Unaudited Financial Results with Limited Review Report for the quarter year ended on December 31, 2024.





## GUJARAT TERCE LABORATORIES LIMITED

Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months ended 31st December, 2024							
Sr. No.	Particulars	[ Rs. in Lakhs except per share detail ]					
		Quarter ended			Nine Months ended		Year ended
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1		2	3	4	5	6	7
I.	Revenue from operations	1268.08	1330.12	1302.02	3787.08	3576.76	4797.47
II.	Other income	6.73	8.05	7.96	22.11	23.93	32.10
III.	<b>Total Revenue ( I+II )</b>	<b>1274.80</b>	<b>1338.17</b>	<b>1309.98</b>	<b>3809.18</b>	<b>3600.69</b>	<b>4829.57</b>
IV.	<b>Expenses:</b>						
	a) Cost of Material consumed	188.37	119.84	173.42	608.70	519.38	758.25
	b) Purchase of stock in trade	284.44	164.70	202.65	747.45	675.85	907.02
	c) Changes in inventories of finished goods, WIP and stock in trade.	-24.63	136.59	46.62	-15.90	61.65	103.80
	d) Employees benefits expenses	397.73	421.05	500.98	1202.35	1535.86	1577.53
	e) Finance Costs	8.45	13.40	16.30	34.68	52.82	67.60
	f) Depreciation and amortisation exp.	9.53	9.44	9.11	28.21	27.34	36.78
	g) Other Expenses	313.14	321.78	293.62	961.49	757.79	1324.19
	<b>Total Expenses</b>	<b>1177.03</b>	<b>1186.80</b>	<b>1242.70</b>	<b>3566.98</b>	<b>3630.69</b>	<b>4775.18</b>
V	<b>Profit/(Loss) before exceptional and Extra ordinary items and Taxes.(III - IV )</b>	<b>97.77</b>	<b>151.37</b>	<b>67.28</b>	<b>242.20</b>	<b>-30.00</b>	<b>54.39</b>
VI	Exceptional items.	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit/(Loss) before extraordinary items and Tax (V-VI)</b>	<b>97.77</b>	<b>151.37</b>	<b>67.28</b>	<b>242.20</b>	<b>-30.00</b>	<b>54.39</b>
VIII	Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
IX	<b>Profit/(Loss) before Tax ( VII-VIII)</b>	<b>97.77</b>	<b>151.37</b>	<b>67.28</b>	<b>242.20</b>	<b>-30.00</b>	<b>54.39</b>
X	<b>Tax Expenses</b>						
	1) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	2) Deferred Tax	-3.03	3.15	0.00	0.94	0.00	30.05
XI	<b>Profit/(Loss) for the period from continuing operations (IX-X)</b>	<b>100.80</b>	<b>148.22</b>	<b>67.28</b>	<b>241.26</b>	<b>-30.00</b>	<b>24.34</b>
XII	<b>Other Comprehensive Income</b>						
	A. (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XIII	<b>Other Comprehensive Income for the period, net of tax</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIV	<b>Total Comprehensive Income for the period (XI+XII)</b>	<b>100.80</b>	<b>148.22</b>	<b>67.28</b>	<b>241.26</b>	<b>-30.00</b>	<b>24.34</b>
XV	<b>Paid up Equity Capital ( at par value of Rs. 10 each)</b>	<b>742.03</b>	<b>742.03</b>	<b>742.03</b>	<b>742.03</b>	<b>742.03</b>	<b>742.03</b>
XVI	<b>Earning per equity share</b>						
	a ) Basic	1.36	2.00	0.91	3.25	-0.40	0.33
	b ) Diluted	1.36	2.00	0.91	3.25	-0.40	0.33
	(See accompanying notes to the Financial Results)						

**Notes:**

- 1 The above Unaudited Standalone financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on February 04, 2025.
- 2 The Limited Review Report for the quarter and nine months ended year ended on 31.12.2024 has been carried out by the statutory auditor, as required under Regulation 33 of SEBI (LODR) Regulation, 2015.
- 3 The Company has adopted Indian Accounting Standard ("Ind AS") notified by the Ministry of Corporate Affairs with effect from April 01, 2017 and accordingly these Unaudited financial results of the company for the quarter ended 31.12.2024 has been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- 4 The Company is operating in single (Pharmaceutical) segment, so above Unaudited Financial Results are for single segment only.
- 5 The figures of the previous quarter / periods has been regrouped/reclassified, wherever necessary.

Place: Ahmedabad

Date: 04/02/2024

For, Gujarat Terce Laboratories Limited

*Aalap Prajapat*



Aalap Prajapat

Managing Director & CEO

DIN: 08088327

**Regd. Office & Factory :** 122/2 Ravi Estate, Bileshwarpura, Chhatral, Ta. : Kalol, Dist. : Gandhinagar (Guj.) INDIA.  
Ph.: 02764-233182 ● E.mail : gtl.factory@gmail.com  
CIN : L28112GJ1985PLC007753

**Admn. Office :** D/801 & 802, The First, Behind Keshavbaug Party Plot, Near Shivalik High-street, Vastrapur, Ahmedabad-380015 Gujarat. (INDIA) ● Ph.: 079-48933  
E.mail : ho@gujaratterce.com ● Web. : www.gujaratterce.com

**CIN: L24100GJ1985PLC007753**



**Limited Review Report for unaudited standalone quarterly results of the Company Pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.**

We have reviewed the accompanying statement of unaudited financial results of Gujarat Terce Laboratories Limited for the quarter ended on December, 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Companies (Indian Accounting Standards) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Date:** 04<sup>th</sup> February 2025

**Place:** Anand

**For, M. A. Shah & Co.**  
Chartered Accountants  
FRN: 0112630W

Prameshbhai  
Bhupendraray Doshi

Digitally signed by Prameshbhai  
Bhupendraray Doshi  
Date: 2025.02.04 11:27:49 +05'30'



**Pramesh Doshi, FCA**  
(Partner)

Mem. No.: 045319

UDIN: 25045319BMISTN8177